



ATTR Amyloidosis Treatment


Presented by: James Ampadu, MD

April 2025

Wild-type ATTR cardiomyopathy	Hereditary ATTR cardiomyopathy	Hereditary ATTR polyneuropathy
Stabilizer	Stabilizer	Silencers • RNA interference therapeutics
Silencers • RNA interference therapeutics	Silencers • RNA interference therapeutics	• Antisense Oligonucleotides


Stabilizers

- Tafamidis / Vyndamax®/ Vyndaqel®
 - TTR stabilizers bind to the TTR tetramer and prevent misfolding and thus deposition of amyloid fibrils
- Route is oral
- Frequency is daily




Stabilizers

- Acoramidis / Attruby™
 - TTR stabilizers bind to the TTR tetramer and prevent misfolding and thus deposition of amyloid fibrils
- Route is oral
- Frequency is twice a day




Silencers-RNA interference therapeutic (RNAi)

- Vutrisiran / Amvuttra®
 - TTR silencers target TTR hepatic synthesis.
 - A chemically modified double-stranded small-interfering RNAs that targets a specific sequence of TTR messenger RNA encoding for transthyretin protein
 - Route is subcutaneous injection by a healthcare professional
 - Frequency is once every 3 months




Silencers-RNA interference therapeutic (RNAi)

- Patisiran / Onpattro®
 - TTR silencers target TTR hepatic synthesis.
- A chemically modified double-stranded small-interfering RNAs that targets a specific sequence of TTR messenger RNA encoding for transthyretin protein
- Route is intravenous by a healthcare professional
- Frequency is once every 3 weeks




Silencers-Antisense Oligonucleotides (ASO)

- Eplontersen / Wainua®
 - TTR silencers target TTR hepatic synthesis.
- ASOs bind to hepatocytes and target specific sequences of TTR messenger RNA encoding for transthyretin protein
- Route is subcutaneous injection (self-administered or HCP)
- Frequency is once every month



Summary of disease-modifying therapies for ATTR

1. TTR stabilizers bind to the TTR tetramer and prevent misfolding and thus deposition of amyloid fibrils.
2. TTR silencers target TTR hepatic synthesis.
3. TTR disruptors target the clearance of amyloid fibrils from tissues.



Adapted from American Heart Association, Inc. Copyright © 2018, Wolters Kluwer Health, Inc